Up to date, a sure cure for Crohn's fistula has not known and the fistula recurrence rate is high. On 15 October 2008, orphan drug designation was granted by Korea FDA to Anterogen Co. Ltd., for human adipose-derived stem cell. In this study, patients are given injection of ADIPOPLUS in fistula site and followed for 8 weeks to test the safety and efficacy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
9
autologous adipose-derived stem cell
Asan medical center
Seoul, South Korea
Efficacy: closure of fistula at week 8 Safety: - Clinically measured abnormality of laboratory tests and adverse events
Closure of fistula
Time frame: week 4
Investigator satisfaction
Time frame: week 4 and week 8
Patient satisfaction
Time frame: week 4 and week 8
Digital photography
Time frame: day 1, week 4 and week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.